BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

881 related articles for article (PubMed ID: 22137134)

  • 1. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
    Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
    Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
    Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
    Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma.
    Scoggins CR; Bowen AL; Martin RC; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; Hagendoorn L; McMasters KM
    Arch Surg; 2010 Jul; 145(7):622-7. PubMed ID: 20644123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and prognostic factors in nodular melanomas.
    Egger ME; Dunki-Jacobs EM; Callender GG; Quillo AR; Scoggins CR; Martin RC; Stromberg AJ; McMasters KM
    Surgery; 2012 Oct; 152(4):652-9; discussion 659-60. PubMed ID: 22925134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic and survival differences between upper and lower extremity melanomas.
    Egger ME; Tabler BL; Dunki-Jacobs EM; Callender GG; Scoggins CR; Martin RC; Quillo AR; Stromberg AJ; McMasters KM
    Am Surg; 2012 Jul; 78(7):779-87. PubMed ID: 22748538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome?
    Fadaki N; Li R; Parrett B; Sanders G; Thummala S; Martineau L; Cardona-Huerta S; Miranda S; Cheng ST; Miller JR; Singer M; Cleaver JE; Kashani-Sabet M; Leong SP
    Ann Surg Oncol; 2013 Sep; 20(9):3089-97. PubMed ID: 23649930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
    Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphovascular invasion as a prognostic factor in melanoma.
    Egger ME; Gilbert JE; Burton AL; McMasters KM; Callender GG; Quillo AR; Brown RE; St Hill CR; Hagendoorn L; Martin RC; Stromberg AJ; Scoggins CR
    Am Surg; 2011 Aug; 77(8):992-7. PubMed ID: 21944512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    MandalĂ  M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients.
    Scoggins CR; Martin RC; Ross MI; Edwards MJ; Reintgen DS; Urist MM; Gershenwald JE; Sussman JJ; Dirk Noyes R; Goydos JS; Beitsch PD; Ariyan S; Stromberg AJ; Hagendoorn LJ; McMasters KM
    Ann Surg Oncol; 2010 Mar; 17(3):709-17. PubMed ID: 19967459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.
    van Akkooi AC; de Wilt JH; Verhoef C; Graveland WJ; van Geel AN; Kliffen M; Eggermont AM
    Eur J Cancer; 2006 Feb; 42(3):372-80. PubMed ID: 16403622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.
    Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E
    Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is incisional biopsy of melanoma harmful?
    Martin RC; Scoggins CR; Ross MI; Reintgen DS; Noyes RD; Edwards MJ; McMasters KM
    Am J Surg; 2005 Dec; 190(6):913-7. PubMed ID: 16307945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
    Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
    Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diversity of stage III melanoma in the era of sentinel lymph node biopsy.
    Egger ME; Callender GG; McMasters KM; Ross MI; Martin RC; Edwards MJ; Urist MM; Noyes RD; Sussman JJ; Reintgen DS; Stromberg AJ; Scoggins CR
    Ann Surg Oncol; 2013 Mar; 20(3):956-63. PubMed ID: 23064795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.